UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

British journal of cancer, 2005-01, Vol.92 (1), p.147-155

2005

Volltextzugriff (PDF)

The impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience

Annals of oncology, 2018-10, Vol.29, p.viii71-viii71

2018

Volltextzugriff (PDF)

The Use of Oncotype DX in Adjuvant Chemotherapy Decision-making in Early Breast Cancer Patients with Intermediate Risk of Mortality at 10 Years

Clinical oncology (Royal College of Radiologists (Great Britain)), 2017-06, Vol.29 (6), p.e103-e103

2017

Volltextzugriff (PDF)

142P Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER+) early breast cancer (EBC): An observational single centre study

Annals of oncology, 2021-05, Vol.32, p.S82

2021

Volltextzugriff (PDF)

Decision-making for Adjuvant Chemotherapy in the Absence of Genomic Testing for Breast Cancer Patients with ‘Intermediate’ Risk of Mortality at 10 Years

Clinical oncology (Royal College of Radiologists (Great Britain)), 2016-05, Vol.28 (5), p.e2-e2

2016

Volltextzugriff (PDF)

Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography

European journal of cancer (1990), 2002, Vol.38 (3), p.375-379

2002

Volltextzugriff (PDF)

Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual

Breast (Edinburgh), 2003-08, Vol.12 (4), p.290-293

2003

Volltextzugriff (PDF)

64 Management of EGFR tyrosine kinase inhibitor associated skin toxicity: a single centre experience

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S23-S23

2016

Volltextzugriff (PDF)

66: Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S26-S26

2015

Volltextzugriff (PDF)

Retrospective Study of the Use of Everolimus/Exemestane in the Treatment of Oestrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC): The Kent Oncology Network Experience

Clinical oncology (Royal College of Radiologists (Great Britain)), 2015-06, Vol.27 (6), p.e10-e10

2015

Volltextzugriff (PDF)

71: Audit of the epidermal growth factor tyrosine kinase (EGFR) and anaplastic lymphoma kinase (ALK) mutation request pathway in non-squamous non-small cell lung cancer (NSCLC) in Kent

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S28-S28

2015

Volltextzugriff (PDF)

139 A retrospective review of lung cancer patients receiving whole brain radiotherapy treated at the Kent Oncology Centre (KOC) in 2014, audited against the QUARTZ trial

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S50-S51

2016

Volltextzugriff (PDF)

Chemotherapy review: Moving to a shared care model

Lung cancer (Amsterdam, Netherlands), 2010, Vol.67, p.S9-S9

2010

Volltextzugriff (PDF)

183 Treating extensive stage small cell lung carcinoma in poor performance status patients – is a high 30 day mortality rate justifiable?

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S68-S68

2014

Volltextzugriff (PDF)

83 Lung cancer diagnosis and management in patients over 80 years – An audit of practice in Kent for 2011/2012

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S31-S31

2014

Volltextzugriff (PDF)

145 Radical chemoradiation in non-small cell lung cancer – does the number of chemotherapy cycles matter?

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S53-S53

2014

Volltextzugriff (PDF)

180 A review of treatment of limited stage small cell lung carcinoma at the Kent Oncology Centre

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S66-S67

2014

Volltextzugriff (PDF)

A systematic review of the role of pulmonary irradiation in the management of primary bone tumours

Annals of oncology, 2002-01, Vol.13 (1), p.23-30

2002

Volltextzugriff (PDF)

Audit of stage III non-small cell lung cancer (NSCLC) management at Maidstone and Tunbridge Wells NHS Trust (MTW)

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.S39

2020

Volltextzugriff (PDF)

14 Audit of the management of epithelial growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients within the Kent Oncology Centre and its associated units

Lung cancer (Amsterdam, Netherlands), 2012, Vol.75, p.S5-S5

2012

Volltextzugriff (PDF)

94 A review of the management of mesothelioma patients who received second line chemotherapy within the Kent Oncology Centre Network

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S33-S33

2013

Volltextzugriff (PDF)

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial

The lancet oncology, 2015-03, Vol.16 (3), p.266-273

2015

Volltextzugriff (PDF)

153 A review of concurrent chemoradiotherapy using cisplatin and oral vinorelbine in patients with non-small cell lung cancer (NCSLC) at the Kent Oncology Centre

Lung cancer (Amsterdam, Netherlands), 2012, Vol.75, p.S50-S50

2012

Volltextzugriff (PDF)

223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Retrospective analysis of EDTA-GFR versus Cockcroft-Gault formula in lung patients receiving carboplatin chemotherapy

Lung cancer (Amsterdam, Netherlands), 2009, Vol.63, p.S7-S7

2009

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(71)
Tagungsberichte
(1)

Sprache

Englisch
(70)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(24)
Pulmonary/respiratory
(20)
Humans
(17)
Science & Technology
(14)
Life Sciences & Biomedicine
(13)
Female
(12)
Oncology
(10)
Adult
(7)
Aged
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Middle Aged
(7)
Breast Cancer
(6)
Breast Neoplasms - Drug Therapy
(6)
Tumors
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Male
(5)
Treatment Outcome
(5)
Breast Neoplasms - Pathology
(4)
Prospective Studies
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

The impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience

The Use of Oncotype DX in Adjuvant Chemotherapy Decision-making in Early Breast Cancer Patients with Intermediate Risk of Mortality at 10 Years

142P Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER+) early breast cancer (EBC): An observational single centre study

Decision-making for Adjuvant Chemotherapy in the Absence of Genomic Testing for Breast Cancer Patients with ‘Intermediate’ Risk of Mortality at 10 Years

Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography

Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual

64 Management of EGFR tyrosine kinase inhibitor associated skin toxicity: a single centre experience

66: Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity

Retrospective Study of the Use of Everolimus/Exemestane in the Treatment of Oestrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC): The Kent Oncology Network Experience

71: Audit of the epidermal growth factor tyrosine kinase (EGFR) and anaplastic lymphoma kinase (ALK) mutation request pathway in non-squamous non-small cell lung cancer (NSCLC) in Kent

139 A retrospective review of lung cancer patients receiving whole brain radiotherapy treated at the Kent Oncology Centre (KOC) in 2014, audited against the QUARTZ trial

Chemotherapy review: Moving to a shared care model

183 Treating extensive stage small cell lung carcinoma in poor performance status patients – is a high 30 day mortality rate justifiable?

83 Lung cancer diagnosis and management in patients over 80 years – An audit of practice in Kent for 2011/2012

145 Radical chemoradiation in non-small cell lung cancer – does the number of chemotherapy cycles matter?

180 A review of treatment of limited stage small cell lung carcinoma at the Kent Oncology Centre

A systematic review of the role of pulmonary irradiation in the management of primary bone tumours

Audit of stage III non-small cell lung cancer (NSCLC) management at Maidstone and Tunbridge Wells NHS Trust (MTW)

14 Audit of the management of epithelial growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients within the Kent Oncology Centre and its associated units

94 A review of the management of mesothelioma patients who received second line chemotherapy within the Kent Oncology Centre Network

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial

153 A review of concurrent chemoradiotherapy using cisplatin and oral vinorelbine in patients with non-small cell lung cancer (NCSLC) at the Kent Oncology Centre

223PThe impact of neoadjuvant dual HER2 targeting with pertuzumab and trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience

Retrospective analysis of EDTA-GFR versus Cockcroft-Gault formula in lung patients receiving carboplatin chemotherapy

Suchergebnisse filtern